CD274 and breast cancer: Although TIL score and PD-L1 expression are suggested as promising indexes to select potentially responsive BC patients to ICB therapy, their translation to clinical practice is limited by non-standardization, complexity and subjectivity in TIL and PD-L1 evaluation.